Background:  One of the main causes of end-stage renal disease worldwide is diabetic nephropathy, a catastrophic microvascular sequel of diabetes. The pathophysiology of DN must thus be urgently investigated in order to develop appropriate remedies. MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1) is anticipated to be a novel target for the detection and therapy of diabetic nephropathy.
Objectives: This research primarily sought to verify the expression of the circulating lncRNA MALAT1 in peripheral blood mononuclear cells (PBMCs) of diabetic patients, diabetic nephropathy, and healthy controls and assess it's relation to disease related criteria
 Patients and methods: 50 diabetic volunteers in this trial sought medical attention at the Outpatient Clinic of Endocrinology & DM at Sohag University Hospital, between January2022 and June 2022 and compare them with 25 apparently healthy persons. The expression of the lncRNA Malat1 was measured using quantitative real-time PCR (qPCR) in 25 people with diabetes, 25 people with DKD, and 25 healthy controls. The clinical relevance of the observations was then assessed.
 Results: As compared to control, LncRNA MALAT1 expression in peripheral blood was substantially higher in the diabetics and DKD groups. Spearman correlation showing significant correlation between RQ and duration of DM as P<0.05, also showing significant correlation between RQ and A/C ratio as P<0.05, there was positive moderate correlation between RQ and HBA1C and showing significant negative correlation between RQ and eGFR as P<0.05.
Conclusion: The best technique to identify diabetic nephropathy may be to combine the detection of urine ACR, serum creatinine, and eGFR with diabetes mellitus. LncRNA Malat1 is substantially expressed in DKD patients compared to diabetics and an apparently healthy group.